PsychonautWiki Archive

Talk:Oxymorphazone: Difference between revisions

← Older edit
>Khuntosaurusrex
More added.
>Tracer
Edit
 
(32 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
 
{{headerpanel|{{Approval}}}}
{{headerpanel|{{proofread}}{{Approval}}}}
{{DepressantOD|opiates}}
{{DepressantOD|opiates}}
{{SubstanceBox
{{SummarySheet}}
{{Talk:SubstanceBox/Oxymorphazone}}


    <!-- Special Parameters -->
'''Oxymorphazone''' (also known as '''oxymorphone hydrazone''') is a semisynthetic [[psychoactive class::opioid]] substance of the [[chemical class::morphinan]] class that produces [[pain relief|analgesic]], [[muscle relaxation|relaxing]], [[sedation|sedating]] and [[euphoria|euphoric]] effects when [[Routes of administration|administered]].
    |displayClasses={{{displayClasses|}}}
    |MaterialTable_MaxWidth=250px
    |MaterialTable_Title={{PAGENAME}}


    <!-- Modules -->
Oxymorphazone is a potent and long acting [[μ-opioid]] [[agonist]] synthesised in 1979 which binds irreversibly to the [[receptor]], forming a covalent bond which prevents it from detaching once bound.<ref>Receptor binding and analgesic properties of oxymorphazone. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/6183551</ref><ref>Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/6176696</ref> This gives it an unusual pharmacological profile, and while oxymorphazone is only around half the potency of [[oxymorphone]], with higher doses the analgesic effect becomes extremely long lasting, with a duration of up to 48 hours.<ref>Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/6206224</ref>
    |ModuleSource=false
    |ModuleCombination=false
    |ModuleStructure=true
    |ModuleNomenclature=true
    |ModuleClassMembership=true
    |ModuleROA=true


    |CombinationImage2_Caption=
==History and culture==
    |CombinationImage2_File=
Oxymorphazone was first synthesised in 1979 by a team of Chemists at Rockefeller University, New York. Recent attempts to build effective irreversible opioid [[agonists]] encouraged the team to develop a hydrazone derivative of [[oxymorphone]].
    |CombinationImage2_Width=
 
    |CombinationImage3_Caption=
    |CombinationImage3_File=
    |CombinationImage3_Width=
 
    <!-- Structure -->
    |MolecularStructureCaption=
    |SkeletalImageFile=File:Oxymorphazone.svg
    |SkeletalImageWidth=245px
    |3DImageFile=
    |3DImageWidth=
 
    <!-- Nomenclature -->
    |NameCommon=Oxymorphazone
    |NameSubstitution=Morphinan-6-one
    |NameSystematic=(5α,6Z)-6-Hydrazono-17-methyl-4,5-epoxymorphinan-3,14-diol
 
    <!-- Class Membership -->
    |EffectClass=[[psychoactive class::Opioid]]
    |ChemicalClass=[[chemical class::Morphinan]]
 
    <!-- Dosage/Duration per ROA -->
 
    |OralROA=true
    |OralROA_Collapsed=false
    |OralROA_Caption=
    |OralROA_Bioavailability=[[Oral min bioavailability::x1]]% - [[Oral max bioavailability::x2]]%<ref>APA formatted citation</ref>
    |OralROA_Microdose=
    |OralROA_Threshold=[[Oral threshold dose::x]] -  [[Oral dose units::mg]]
    |OralROA_Light=[[Oral min light dose::x1]] - [[Oral max light dose::x2]] mg
    |OralROA_Common=[[Oral min common dose::x1]] - [[Oral max common dose::x2]] mg
    |OralROA_Strong=[[Oral min strong dose::x1]] - [[Oral max strong dose::x2]] mg
    |OralROA_Heavy=[[Oral heavy dose::x]] mg +
    |OralROA_TimelineFile=
    |OralROA_TimelineWidth=
    |OralROA_Duration=[[Oral min total time::x1]] - [[Oral max total time::x2]] [[Oral total time units::hours]]
    |OralROA_Onset=[[Oral min onset time::x1]] - [[Oral max onset time::x2]] [[Oral onset time units::minutes]]
    |OralROA_Comeup=[[Oral min comeup time::x1]] - [[Oral max comeup time::x2]] [[Oral comeup time units::minutes]]
    |OralROA_Peak=[[Oral min peak time::x1]] - [[Oral max peak time::x2]] [[Oral peak time units::hours]]
    |OralROA_Offset=[[Oral min offset time::x1]] - [[Oral max offset time::x2]] [[Oral offset time units::hours]]
    |OralROA_Aftereffects=[[Oral min afterglow time::x1]] - [[Oral max afterglow time::x2]] [[Oral afterglow time units::hours]]
 
 
    |IntravenousROA=false
    |IntravenousROA_Collapsed=true
    |IntravenousROA_Caption=
    |IntravenousROA_Bioavailability=[[Intravenous min bioavailability::x1]]% - [[Intravenous max bioavailability::x2]]%<ref>APA formatted citation</ref>
    |IntravenousROA_Microdose=
    |IntravenousROA_Threshold=[[Intravenous threshold dose::x]] -  [[Intravenous dose units::mg]]
    |IntravenousROA_Light=[[Intravenous min light dose::x1]] - [[Intravenous max light dose::x2]] mg
    |IntravenousROA_Common=[[Intravenous min common dose::x1]] - [[Intravenous max common dose::x2]] mg
    |IntravenousROA_Strong=[[Intravenous min strong dose::x1]] - [[Intravenous max strong dose::x2]] mg
    |IntravenousROA_Heavy=[[Intravenous heavy dose::x]] mg +
    |IntravenousROA_TimelineFile=
    |IntravenousROA_TimelineWidth=
    |IntravenousROA_Duration=[[Intravenous min total time::x1]] - [[Intravenous max total time::x2]] [[Intravenous total time units::hours]]
    |IntravenousROA_Onset=[[Intravenous min onset time::x1]] - [[Intravenous max onset time::x2]] [[Intravenous onset time units::minutes]]
    |IntravenousROA_Comeup=[[Intravenous min comeup time::x1]] - [[Intravenous max comeup time::x2]] [[Intravenous comeup time units::minutes]]
    |IntravenousROA_Peak=[[Intravenous min peak time::x1]] - [[Intravenous max peak time::x2]] [[Intravenous peak time units::hours]]
    |IntravenousROA_Offset=[[Intravenous min offset time::x1]] - [[Intravenous max offset time::x2]] [[Intravenous offset time units::hours]]
    |IntravenousROA_Aftereffects=[[Intravenous min afterglow time::x1]] - [[Intravenous max afterglow time::x2]] [[Intravenous afterglow time units::hours]]
}}


 
There is no documented human consumption of oxymorphazone. This is potentially due to its high addiction liability and extremely long duration.
==History and culture==
Oxymorphazone was first synthesised in 1979 by a team of Chemists at Rockefeller University, New York. Recent attempts to build effective irreversible opioid [[agonists]] encouraged the team to develop a hydrazone derivative of oxymorphone.


==Chemistry==
==Chemistry==
{{chemistry}}
Oxymorphazone is an opioid of the morphinan class. Oxymorphazone and other molecules of this class contain a polycyclic core of three benzene rings fused in a zig-zag pattern called phenanthrene. A fourth nitrogen containing ring is fused to the phenanthrene at R<sub>9</sub> and R<sub>13</sub> with the nitrogen member looking at R<sub>17</sub> of the combined structure. This structure is called [[morphinan]]. Oxymorphazone is structurally similar to [[oxymorphone]], with a C<sub>6</sub> substitution of oxygen with a hydrazone group.
Oxymorphazone is an opioid of the morphinan class. Oxymorphazone and other molecules of this class contain a polycyclic core of three benzene rings fused in a zig-zag pattern called phenanthrene. A fourth nitrogen containing ring is fused to the phenanthrene at R<sub>9</sub> and R<sub>13</sub> with the nitrogen member looking at R<sub>17</sub> of the combined structure. This structure is called morphinan. Oxymorphazone is structurally similar to Oxymorphone, with a C<sub>6</sub> substitution of oxygen with a hydrazone group.


==Pharmacology==
==Pharmacology==
{{pharmacology}}
Oxymorphazone is long acting, irreversible [[μ-opioid]] [[receptor]] (MOR) agonist. This occurs due to the way in which opioids structurally mimic endogenous endorphins. Endorphins are responsible for analgesia (reducing pain), causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or excitement. This mimicking of natural endorphins results in the drug's [[physical euphoria|euphoric]], [[pain relief|analgesic]] (pain relief), and [[anxiety suppression|anxiolytic]] (anti-anxiety) effects.
Oxymorphazone is long acting, irreversible [[μ-opioid]] [[receptor]] (MOR) agonist. This occurs due to the way in which opioids structurally mimic endogenous endorphins. Endorphins are responsible for analgesia (reducing pain), causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or excitement. This mimicking of natural endorphins results in the drug's [[physical euphoria|euphoric]], [[pain relief|analgesic]] (pain relief), and [[anxiety suppression|anxiolytic]] (anti-anxiety) effects.


These appear to stem from the way in which [[opioids]] mimic endogenous endorphins. Endorphins are responsible for analgesia (reducing pain), causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or excitement. This mimicking of natural endorphins results in the drug's effects.
These appear to stem from the way in which [[opioids]] mimic endogenous endorphins. Endorphins are responsible for analgesia (reducing pain), causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or excitement. This mimicking of natural endorphins results in the drug's effects.


Oxymorphazone is estimated to be 50-100% as potent as [[oxymorphone]]<ref name = "a">[Ling, G., Galetta, S., & Pasternak, G. (1984). Oxymorphazone: A long-acting opiate analgesic. Cellular And Molecular Neurobiology, 4(1), 1-13. doi: 10.1007/bf00710938]</ref>. Although oxymorphazone is active on its own, research suggests that oxymorphazone's extremely long duration of effects and irreversible binding is a result of rapid degradation to oxymorphonazine. Oxymorphonazine is some 20-40x more potent and forms a covalent bond with the MOR, causing extensively long clearance.
Oxymorphazone is estimated to be 50-100% as potent as [[oxymorphone]].<ref name="LingGaletta1984">{{cite journal|last1=Ling|first1=Geoffrey S. F.|last2=Galetta|first2=Steven|last3=Pasternak|first3=Gavril W.|title=Oxymorphazone: A long-acting opiate analgesic|journal=Cellular and Molecular Neurobiology|volume=4|issue=1|year=1984|pages=1–13|issn=0272-4340|doi=10.1007/BF00710938}}</ref> Although oxymorphazone is active on its own, research suggests that oxymorphazone's extremely long duration of effects and irreversible binding is a result of rapid degradation to oxymorphonazine. Oxymorphonazine is some 20-40x more potent and forms a covalent bond with the MOR, causing extensively long clearance.


Due to strong binding affinity and it's long action, tolerance to oxymorphazone builds very rapidly<ref name= "a" /> and physical dependence is guaranteed, even from just one administration of the substance.
Due to strong binding affinity and its long action, tolerance to oxymorphazone builds very rapidly<ref name= "LingGaletta1984" /> and physical dependence is guaranteed, even from just one administration of the substance.


==Subjective effects==
==Subjective effects==
{{EffectStub}}
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base
|{{effects/physical|
|{{effects/physical|
If applicable, a brief paragraph summary of the substance's physical effects may be included here.
*'''[[Effect::Physical euphoria|Euphoria]]'''
 
*'''[[Effect::Constipation]]'''
You may select physical effects to add below [[Subjective effect index#Physical effects|here]].
*'''[[Effect::Decreased libido]]'''
 
*'''[[Effect::Difficulty urinating]]'''
*'''[[Effect::Physical effect]]'''  
*'''[[Effect::Itchiness]]'''
*'''[[Effect::Physical effect2]]'''
*'''[[Effect::Nausea]]'''
*'''[[Effect::Physical effect3]]'''
*'''[[Effect::Pain relief]]'''
*'''[[Effect::Pupil constriction]]'''
*'''[[Effect::Respiratory depression]]'''
*'''[[Effect::Sedation]]'''
*'''[[Effect::Skin flushing]]'''
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Orgasm suppression]]'''


}}
}}
{{effects/visual|
If applicable, a brief paragraph summary of the substance's visual effects may be included here.


You may select visual effects to add below [[Subjective effect index#Visual effects|here]].
====Enhancements====
*'''[[Effect::Visual acuity effect1]]'''
====Distortions====
*'''[[Effect::Visual distortion effect1]]'''
====[[Effect::Geometry]]====
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
====Hallucinatory states====
If applicable, a brief summary of the substance's visual effects profile may be written here.
*'''[[Effect::Hallucinatory states1]]'''
}}


|{{effects/cognitive|
|{{effects/cognitive|
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
*'''[[Effect::Cognitive euphoria|Euphoria]]'''
 
*'''[[Effect::Anxiety suppression]]'''
You may select from a list of cognitive effects to add below [[Subjective effect index#Cognitive effects|here]].
*'''[[Effect::Compulsive redosing]]'''
 
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Cognitive effect1]]'''  
*'''[[Effect::Cognitive effect2]]'''  
*'''[[Effect::Cognitive effect3]]'''  


}}
}}
{{effects/auditory|
{{effects/visual|
If applicable, a brief paragraph summary of the substance's auditory effects may be included here.
*'''[[Effect::Internal hallucination]]''' - One may experience a state of semi-consciousness and [[hypnagogia]] during heavy dosage nodding which results in dream-like states and up to level 3 [[Lucid_dreaming#Internally_sourced_sensory_input|imagery]]. This is often accompanied by ill-defined [[geometry]].
 
You may select from a list of auditory effects to add below [[Subjective effect index#Auditory effects|here]].
 
*'''[[Effect::Auditory effect1]]'''
*'''[[Effect::Auditory effect2]]'''
 
}}
{{effects/multisensory|
If applicable, a brief paragraph summary of the substance's multisensory effects may be included here.
 
You may select from a list of multisensory effects to add below [[Subjective effect index#Multisensory effects|here]].
 
*'''[[Effect::Multisensory effect1]]'''
*'''[[Effect::Multisensory effect2]]'''
 
}}
}}
{{effects/transpersonal|
If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here.
You may select from a list of transpersonal effects to add below [[Subjective effect index#Transpersonal effects|here]].
*'''[[Effect::Transpersonal effect1]]'''
*'''[[Effect::Transpersonal effect2]]'''


}}
}}
}}


===Experience reports===
===Experience reports===


There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
There are currently {{#ask:[[Category:Oxymorphazone]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
{{#ask: [[Category:SUBSTANCE]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:SUBSTANCE]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_SUBSTANCE.shtml Erowid Experience Vaults: SUBSTANCE] <!-- Check the link to see if it exists -->


==Toxicity and harm potential==
==Toxicity and harm potential==
{{toxicity}}
{{toxicity}}
Oxymorphazone has a [[Toxicity::low toxicity]] relative to dose. It is estimated to be half to 100% as potent as oxymorphpne, suggesting that 10mg oxymorphazone is equivalent to approximately 30mg [[morphine]].<ref name="PergolizziRaffa2009">{{cite journal|last1=Pergolizzi|first1=Joseph V.|last2=Raffa|first2=Robert B.|title=Oxymorphone and Opioid Rotation|journal=Pain Medicine|volume=10|issue=suppl 1|year=2009|pages=S39–S48|issn=1526-2375|doi=10.1111/j.1526-4637.2009.00598.x}}</ref> As with all opioids, long-term effects can vary but can include diminished libido, apathy, and memory loss. It is also [[Toxicity::potentially [[respiratory depression|lethal]] when mixed with [[depressants]] like [[alcohol]] or [[benzodiazepines]]]].
Oxymorphazone use is considered '''extremely''' dangerous. This is because if overdose occurs, antagonism of the [[μ-opioid]] [[receptor]] is not possible. Drugs such as [[naloxone]] are unable to knock oxymorphazone off the MOR, and as such are useless in treating oxymorphazone overdose. There are no MOR hydrazone [[antagonists]] (that would knock oxymorphazone off the MOR) on the market. Treatment of oxymorphazone overdose would be supportive care (such as mechanical ventilation) and ensuring the patient does not aspirate on their vomit.
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
===Lethal dosage===
 
===Tolerance and addiction potential===
===Tolerance and addiction potential===
As with other [[opioids]], the chronic use of oxymorphazone can be considered [[Addiction potential::extremely addictive with a high potential for abuse]] and is capable of causing psychological and physical dependence among certain users. A single administration of oxymorphazone results in physical dependence in rats<ref name= "LingGaletta1984" /> . Tolerance also builds extremely rapidly, due to its prolonged effects. Thus, although oxymorphazone may have similar subjective effects to oxymorphone, it is likely addiction would develop in a much larger proportion of users. When addiction has developed, cravings and [[Opioids#Discontinuation|withdrawal symptoms]] may occur if a person suddenly stops their usage.
Tolerance to many of the effects of oxymorphazone [[Time to full tolerance::develops with prolonged and repeated use]]. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). Oxymorphazone presents cross-tolerance with [[Cross-tolerance::all other [[opioids]]]], meaning that after the consumption of oxymorphazone all [[opioid]]s will have a reduced effect.
The risk of fatal opioid overdoses rise sharply after a period of cessation and [[relapse]], largely because of reduced tolerance.<ref>Friedman, L. F. (2014, February 03). Why heroin relapse often ends in death. Retrieved from http://www.businessinsider.com.au/philip-seymour-hoffman-overdose-2014-2</ref> To account for this lack of tolerance, it is safer to only dose a fraction of one's usual [[dosage]] if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of oxymorphazone administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.<ref name="SiegelHinson1982">{{cite journal|last1=Siegel|first1=S|last2=Hinson|first2=R.|last3=Krank|first3=M.|last4=McCully|first4=J|title=Heroin "overdose" death: contribution of drug-associated environmental cues|journal=Science|volume=216|issue=4544|year=1982|pages=436–437|issn=0036-8075|doi=10.1126/science.7200260}}</ref>
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Depressants}}


==Legal status==
==Legal status==
{{LegalStub}}
*'''United Kingdom''' - Oxymorphazone is a Class A, Schedule 2 drug in the United Kingdom. It has no medical uses. <ref>Psychoactive Substances Act 2016. (2016). Retrieved from http://www.legislation.gov.uk/ukpga/2016/2/schedule/2/enacted</ref>
*'''United States''' - Oxymorphazone is a Schedule I Controlled Substance in the United States. It is considered to be unsafe and holds no medical value. <ref> Drug Enforcement Administration Controlled Substances | https://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf</ref>
 


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
==External links==
*[[Oxymorphone]]
(List along order below)
*[[Opioid]]
* [https://en.wikipedia.org/wiki/SUBSTANCE SUBSTANCE (Wikipedia)]
*[[Depressants]]
* SUBSTANCE (Erowid Vault)
*[[Naloxone]]
* SUBSTANCE ([''PiHKAL'' or ''TiHKAL''] / Isomer Design)


==Literature==
* APA formatted reference


Please see the [[citation formatting guide]] if you need assistance properly formatting citations.
==External links==
*[https://en.wikipedia.org/wiki/Oxymorphazone Oxymorphazone (Wikipedia)]


==References==
==References==
<references />
<references />
 
[[Category:Proofread]]
[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]
[[Category:Approval]]
[[Category:Psychoactive substance]]
[[Category:Morphinan]]
[[Category:Depressant]]
[[Category:Opioid]]
Retrieved from "https://psy.st/wiki/Talk:Oxymorphazone"
Return to "Oxymorphazone" page.